Producto


R&D INNOVATION PIPELINE
ASCIL's R&D INNOVATION PIPELINE includes proprietary DDS products, technologies and devices in proof-of-concept study or in preparation for clinical development based on 3 axes of an integrated strategy: PROFILE, FOCUS, ADAPT.
 
ASCIL's R&D INNOVATION PIPELINE includes proprietary DDS products, technologies and devices in proof-of-concept study or in preparation for clinical development based on 3 axes of an integrated strategy: PROFILE, FOCUS, ADAPT.


BIOPHARMACEUTICAL CONTROL RELEASE of FORMULATIONS
PROFILE: Ascil’s expertise focuses on developing improved controlled release profiles for small molecules, peptides and proteins that result in better longer acting and optimized injectable products. The current pipeline includes:
-Formulations for up to quarterly administration of high dose biologics (>300mg/mL)
-Immediate release ready-to-use DDS of emergency drugs and peptides for chronic use at ug doses.


FOCUSED LOCAL ACTION
Two R&D programs focused on concentrated locally acting DDS as a way to achieve improved product performance and avoid systemic exposure related to known safety issues:
-Intravitreal long acting products
-Dermo-cosmetic targeted delivery technologies for improved skin health.


ADAPT: NOVEL DRUG PRODUCT-DEVICE COMBINATIONS
New formulation, device process solutions adapted for the delivery of complex medicines:
-New device for micro-dosing (down to 2.5uL)
-Ready-to-use lyophilized alternatives to dual-chamber devices.
 
 
 
 
Permalink  
 
Desarrollado por Web4Bio